[DOI] [PubMed] [Google Scholar] 227.Rroji M, Spasovski G
Zhu H, Zhou L, Wang Q, Cai Q, Yang F, Jin H, Chen Y, Song Y, Zhang C (2023) Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort
Noom GLP 1Program Review programs blend cutting-edge medication, world-class digital coaching, and adaptive dosing for those struggling with weight loss plateaus, obesity, or metabolic challenges
In line with reports indicating that PPAR may act on hypothalamic neurocircuitries 5,6 , we identified a series of new PPAR protein targets in the hypothalamus that are acutely upregulated by tesaglitazar and by GLP-1RA/tesaglitazar, but not by treatment with the GLP-1RA